But until then, the reference standard of practice will remain that of fixed activity, which has prevailed since the introduction of 131I for thyroid cancer until today, with the recent approval of empiric 177Lu-PSMA-617 RLT for prostate cancer [2]. This evidence concerns the gene FOLH1 and Familial prostate cancer.